C WorldWide Group Holding A S increased its position in shares of Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 32.3% during the second quarter, Holdings Channel reports. The institutional investor owned 248,800 shares of the biotechnology company’s stock after buying an additional 60,700 shares during the period. C WorldWide Group Holding A S’s holdings in Aimmune Therapeutics were worth $5,115,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock worth $50,339,000 after buying an additional 2,004,023 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Aimmune Therapeutics by 4.9% in the first quarter. Alliancebernstein L.P. now owns 750,640 shares of the biotechnology company’s stock worth $16,311,000 after buying an additional 34,913 shares in the last quarter. American International Group Inc. raised its position in shares of Aimmune Therapeutics by 7.1% in the first quarter. American International Group Inc. now owns 16,184 shares of the biotechnology company’s stock worth $352,000 after buying an additional 1,070 shares in the last quarter. Victory Capital Management Inc. bought a new position in shares of Aimmune Therapeutics during the first quarter worth approximately $1,064,000. Finally, Swiss National Bank raised its position in shares of Aimmune Therapeutics by 17.5% in the first quarter. Swiss National Bank now owns 36,974 shares of the biotechnology company’s stock worth $803,000 after buying an additional 5,500 shares in the last quarter. 69.51% of the stock is currently owned by institutional investors and hedge funds.

Shares of Aimmune Therapeutics, Inc. (AIMT) opened at 18.98 on Friday. Aimmune Therapeutics, Inc. has a 12-month low of $12.38 and a 12-month high of $27.31. The firm has a 50-day moving average price of $20.99 and a 200-day moving average price of $19.94. The firm’s market cap is $959.15 million.

Aimmune Therapeutics (NASDAQ:AIMT) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.64) by $0.01. Equities research analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.68) EPS for the current year.

ILLEGAL ACTIVITY WARNING: This article was reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/11/c-worldwide-group-holding-a-s-has-5-12-million-position-in-aimmune-therapeutics-inc-nasdaqaimt.html.

A number of brokerages have recently commented on AIMT. Wedbush reissued an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, July 24th. Zacks Investment Research lowered Aimmune Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, July 27th. Piper Jaffray Companies set a $38.00 price objective on Aimmune Therapeutics and gave the company a “buy” rating in a report on Thursday, July 27th. Finally, ValuEngine raised Aimmune Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, June 13th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. Aimmune Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $33.00.

In other Aimmune Therapeutics news, insider Stephen George Dilly sold 50,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 26th. The stock was sold at an average price of $21.46, for a total value of $1,073,000.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Susan E. Barrowcliffe sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $20.26, for a total value of $303,900.00. Following the completion of the sale, the insider now owns 15,000 shares in the company, valued at approximately $303,900. The disclosure for this sale can be found here. Insiders sold 188,470 shares of company stock worth $3,942,092 in the last 90 days. Corporate insiders own 24.56% of the company’s stock.

About Aimmune Therapeutics

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Want to see what other hedge funds are holding AIMT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aimmune Therapeutics, Inc. (NASDAQ:AIMT).

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.